235 related articles for article (PubMed ID: 30915997)
1. Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal.
Algera MH; Kamp J; van der Schrier R; van Velzen M; Niesters M; Aarts L; Dahan A; Olofsen E
Br J Anaesth; 2019 Jun; 122(6):e168-e179. PubMed ID: 30915997
[TBL] [Abstract][Full Text] [Related]
2. Reversal of opioid-induced respiratory depression by BK-channel blocker GAL021: A pharmacokinetic-pharmacodynamic modeling study in healthy volunteers.
Roozekrans M; Olofsen E; van der Schrier R; van Gerven J; Peng S; McLeod J; Dahan A
Clin Pharmacol Ther; 2015 Jun; 97(6):641-9. PubMed ID: 25704491
[TBL] [Abstract][Full Text] [Related]
3. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest.
van Lemmen M; Florian J; Li Z; van Velzen M; van Dorp E; Niesters M; Sarton E; Olofsen E; van der Schrier R; Strauss DG; Dahan A
Anesthesiology; 2023 Sep; 139(3):342-353. PubMed ID: 37402248
[TBL] [Abstract][Full Text] [Related]
4. Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.
Yassen A; Olofsen E; van Dorp E; Sarton E; Teppema L; Danhof M; Dahan A
Clin Pharmacokinet; 2007; 46(11):965-80. PubMed ID: 17922561
[TBL] [Abstract][Full Text] [Related]
5. Advances in Reversal Strategies of Opioid-induced Respiratory Toxicity.
van der Schrier R; Dahan JDC; Boon M; Sarton E; van Velzen M; Niesters M; Dahan A
Anesthesiology; 2022 Apr; 136(4):618-632. PubMed ID: 34958670
[TBL] [Abstract][Full Text] [Related]
6. Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?
Algera MH; Cotten JF; van Velzen M; Niesters M; Boon M; Shoham DS; Dandrea KE; van der Schrier R; Dahan A
Pharmacol Res Perspect; 2022 Jun; 10(3):e00974. PubMed ID: 35621218
[TBL] [Abstract][Full Text] [Related]
7. Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteers.
Roozekrans M; van der Schrier R; Okkerse P; Hay J; McLeod JF; Dahan A
Anesthesiology; 2014 Sep; 121(3):459-68. PubMed ID: 25222672
[TBL] [Abstract][Full Text] [Related]
8. Non-analgesic effects of opioids: opioid-induced respiratory depression.
Boom M; Niesters M; Sarton E; Aarts L; Smith TW; Dahan A
Curr Pharm Des; 2012; 18(37):5994-6004. PubMed ID: 22747535
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of viable mechanism agnostic respiratory stimulants for the reversal of drug-induced respiratory depression in humans.
van Lemmen M; van der Schrier R; Dahan A; van Velzen M; Sarton E; Niesters M
Expert Opin Drug Metab Toxicol; 2023; 19(10):671-679. PubMed ID: 37795596
[TBL] [Abstract][Full Text] [Related]
10. Averting Opioid-induced Respiratory Depression without Affecting Analgesia.
Dahan A; van der Schrier R; Smith T; Aarts L; van Velzen M; Niesters M
Anesthesiology; 2018 May; 128(5):1027-1037. PubMed ID: 29553984
[TBL] [Abstract][Full Text] [Related]
11. Opioid-induced respiratory effects: new data on buprenorphine.
Dahan A
Palliat Med; 2006; 20 Suppl 1():s3-8. PubMed ID: 16764215
[TBL] [Abstract][Full Text] [Related]
12. The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression.
Lötsch J; Skarke C; Schneider A; Hummel T; Geisslinger G
Clin Pharmacol Ther; 2005 Sep; 78(3):278-87. PubMed ID: 16153398
[TBL] [Abstract][Full Text] [Related]
13. Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression.
Dahan A; Aarts L; Smith TW
Anesthesiology; 2010 Jan; 112(1):226-38. PubMed ID: 20010421
[TBL] [Abstract][Full Text] [Related]
14. The conundrum of polysubstance overdose.
Pergolizzi JV; Dahan A; LeQuang JA; Raffa RB
J Clin Pharm Ther; 2021 Oct; 46(5):1189-1193. PubMed ID: 33460173
[TBL] [Abstract][Full Text] [Related]
15. Doxapram-mediated Increase in Cardiac Output Reduces Opioid Plasma Concentrations: A Pharmacokinetic/Pharmacodynamic-Pharmacokinetic/Pharmacodynamic Modeling Study in Healthy Volunteers.
Roozekrans M; Olofsen E; van der Schrier R; Boom M; Mooren R; Dahan A
Clin Pharmacol Ther; 2017 Jul; 102(1):115-122. PubMed ID: 28001306
[TBL] [Abstract][Full Text] [Related]
16. Esketamine counters opioid-induced respiratory depression.
Jonkman K; van Rijnsoever E; Olofsen E; Aarts L; Sarton E; van Velzen M; Niesters M; Dahan A
Br J Anaesth; 2018 May; 120(5):1117-1127. PubMed ID: 29661389
[TBL] [Abstract][Full Text] [Related]
17. Theophylline reverses oxycodone's but not fentanyl's respiratory depression in mice while caffeine is ineffective against both opioids.
Elder HJ; Walentiny DM; Beardsley PM
Pharmacol Biochem Behav; 2023 Aug; 229():173601. PubMed ID: 37414364
[TBL] [Abstract][Full Text] [Related]
18. Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone.
Ellison M; Hutton E; Webster L; Skolnick P
J Clin Pharmacol; 2024 Jul; 64(7):828-839. PubMed ID: 38436495
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and preliminary evaluation of a potential synthetic opioid rescue agent.
Hedrick SL; Luo D; Kaska S; Niloy KK; Jackson K; Sarma R; Horn J; Baynard C; Leggas M; Butelman ER; Kreek MJ; Prisinzano TE
J Biomed Sci; 2021 Sep; 28(1):62. PubMed ID: 34503531
[TBL] [Abstract][Full Text] [Related]
20. Opioid-induced respiratory depression: reversal by non-opioid drugs.
van der Schier R; Roozekrans M; van Velzen M; Dahan A; Niesters M
F1000Prime Rep; 2014; 6():79. PubMed ID: 25343036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
